Chemotherapy with gemcitabine for unresectable intrahepatic cholangiocarcinoma in a patient undergoing maintenance hemodialysis

Clin J Gastroenterol. 2021 Oct;14(5):1511-1516. doi: 10.1007/s12328-021-01478-4. Epub 2021 Jul 9.

Abstract

A 56-year-old man with chronic renal failure due to diabetic nephropathy had received maintenance dialysis (every 4 h, three times/week). A hypoechoic tumor measuring 67 × 50 mm in the right lobe of the liver was discovered following routine abdominal ultrasonography. Dynamic computed tomography showed a low-density liver tumor, enlarged hilar lymph node, and a small nodule on the dorsal side of the lower lobe of the left lung. Histopathological examination of the liver tumor revealed intrahepatic cholangiocarcinoma. We developed a chemotherapy treatment plan with gemcitabine, which can be performed concurrently with hemodialysis. Gemcitabine (1000 mg/m2, three times/cycle) was administered on Friday afternoon, and hemodialysis was performed on Tuesday, Thursday, and Saturday. Anemia and hypotension occurred after gemcitabine administration. Therefore, the dose of darbepoetin alpha was increased, and packed red blood cells were transfused. The patient was treated with gemcitabine for approximately 5 and a half months until computed tomography findings showed progressive disease; the survival time after treatment start was 8 months. Chemotherapy using gemcitabine has not been established in dialysis patients and has little evidence. We report a case of unresectable intrahepatic cholangiocarcinoma that developed during maintenance dialysis and was treated using gemcitabine chemotherapy.

Keywords: Gemcitabine; Hemodialysis; Intrahepatic cholangiocarcinoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bile Duct Neoplasms* / complications
  • Bile Duct Neoplasms* / drug therapy
  • Cholangiocarcinoma* / complications
  • Cholangiocarcinoma* / drug therapy
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Gemcitabine
  • Humans
  • Male
  • Middle Aged
  • Renal Dialysis

Substances

  • Deoxycytidine
  • Gemcitabine